On Friday, January 5, the Federal Trade Commission gave Endo Pharmaceuticals the go-ahead to weigh in on the government’s administrative proceeding against Impax Laboratories. The case alleges that a 2010 settlement between the companies allowing Endo to introduce a generic version of Impax’s Opana ER had no pro-competitive justifications.
Endo will be allowed to submit a brief opposing the government’s request for relief in its action against Impax that could potentially affect or nullify a second settlement reached between the two pharmaceutical companies in 2017.
The original complaint in 2012, accused Endo in 2012 of working a deal in which they compensated Watson Laboratories “hundreds of millions of dollars” to hold off a generic version of Endo’s Lidoderm patch. It also accused Endo of paying Impax $112 million in 2010 to hold off releasing an authorized generic version of Endo’s painkiller Opana. The FTC alleged Endo’s financial gain by giving it time to transition patients to a new formulation of Opana ER, “thereby maintaining its monopoly power.”
Full Content: Federal Trade Commission and Global Competition Review
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
NCAA and SEC Approve Historic $2.8 Billion Settlement in Antitrust Cases
May 23, 2024 by
CPI
Apple Defends 27% Fee in Compliance with Court Order, Phil Schiller Testifies
May 23, 2024 by
CPI
French Billionaire Xavier Niel Eyes $4 Billion Millicom Buyout
May 23, 2024 by
CPI
ITA-Lufthansa Merger Faces Scrutiny from European Commission
May 23, 2024 by
CPI
Google Explores Major Acquisition of HubSpot to Bolster Cloud
May 23, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI